Health Canada issues warning on over-dosage morphine tablets
This article was originally published in Scrip
Health Canada has issued a warning about ratio-Morphine SR tablets, as some may contain more morphine than indicated. Morphine SR 15mg, 30mg and 60mg tablets with above-stated doses of morphine, reported to be noticeably thicker than the regular tablets, were found to be on the Canadian market after US manufacturer KV Pharmaceutical received two complaints, prompting the Canadian distributor Ratiopharm to initiate a recall of the affected lots, with a separate communication being prepared for doctors and pharmacists. Patients currently using ratio-Morphine SR tablets of the affected doses are advised to contact their physician for an alternative and return products to a pharmacist for safe disposal. As of June 30th, no adverse reactions had been reported to Health Canada.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).